Skip to main content
Lippincott Open Access logoLink to Lippincott Open Access
. 2023 Aug 22;30(10):1038–1044. doi: 10.1097/GME.0000000000002235

Association between perimenopausal age and greater posttraumatic stress disorder and depression symptoms in trauma-exposed women

Vasiliki Michopoulos 1, Megan E Huibregtse 1, E Britton Chahine 2, Alicia K Smith 1,2, Ida T Fonkoue 3,4, Jessica Maples-Keller 1, Amy Murphy 1, Linzie Taylor 1, Abigail Powers 1, Jennifer S Stevens 1
PMCID: PMC10527101  NIHMSID: NIHMS1911054  PMID: 37610715

Posttraumatic stress disorder and depression symptoms in trauma-exposed women are impacted by reproductive age, such that perimenopausal women show higher symptom severity than premenopausal and postmenopausal women.

Key Words: Depression, Menopause, PTSD, Trauma

Abstract

Objective

This study aimed to determine the relationship between stages of the menopause transition (premenopausal, perimenopausal, and postmenopausal) on symptoms of posttraumatic stress disorder (PTSD) and depression in trauma-exposed women.

Methods

A cross-sectional study conducted between 2005 and 2017 recruited and enrolled an urban community sample (n = 6,093) from nonpsychiatric medical clinic waiting rooms of Grady Memorial Hospital, a public safety net hospital in Atlanta, Georgia. Participants were female, 18 to 65 years old, and predominantly Black/African American.

Results

Of the 6,093 participants, 93.8% were Black/African American, 2.5% were White, and 3.8% were of all other races (Hispanic/Latino, Asian, multiracial). Participants younger than 40 years were categorized as premenopausal (n = 3,166), between 40 and 55 years of age were categorized as perimenopausal (n = 2,127), and older than 55 years were categorized as postmenopausal (n = 790). Menopause status was associated with total PTSD symptom severity (F2,5416 = 9.61, P < 0.001), symptom severity within all three PTSD symptom clusters (avoidance/numbing symptoms: F2,5416 = 7.10, P < 0.001; intrusive symptoms: F2,5416 = 7.04, P < 0.001; hyperarousal symptoms: F2,5409 = 8.31, P < 0.001), and depression symptom severity (F2,5148 = 11.4, P < 0.001). Compared with both premenopausal and postmenopausal women, perimenopausal women reported significantly worse total PTSD symptoms, symptoms in the hyperarousal cluster, and depressive symptoms.

Conclusions

The current cross-sectional data show that symptoms of PTSD and depression in women are associated with reproductive age, such that perimenopausal women show higher symptom severity than premenopausal and postmenopausal women. Future longitudinal studies can reveal how changes in hormones over the course of the menopause transition impact the symptoms, neurobiology, and psychophysiology of PTSD.


Ninety percent of people have experienced at least one traumatic event in their lifetime.1 Trauma exposure and resulting adverse mental health sequelae including posttraumatic stress disorder (PTSD) and depression are all associated with increased rates of chronic medical conditions and increased mortality.2-6 Certain risk factors, including race/ethnicity, socioeconomic status, and female sex, increase the likelihood of trauma exposure and subsequent development of PTSD. Predominantly Black/African American communities in urban, lower socioeconomic areas experience greater rates of lifetime trauma exposure, which is associated with increased risk for PTSD.1,7 In addition, PTSD and depression, two common psychiatric outcomes following trauma exposure, are more than twice as prevalent in women than men.1,8,9 Natural hormonal variation across the female lifespan is linked to increased risk for depressive and anxiety symptoms,10,11 and premenopausal women with lower estradiol (E2) levels exhibit impaired fear extinction and greater severity of PTSD symptoms.12–14 However, even less is known regarding neuropsychiatric health in women during other reproductive stages, such as pregnancy and the menopausal transition.

During the transition to menopause, menstrual cycles become irregular as ovarian reserve declines.15 This perimenopausal window is a known risk factors for depression16 and a critical window for clinical intervention. For example, hormone therapies are most effective when administered perimenopausally in mitigating both depression17 and the onset and progression of neurological disorders such as Alzheimer disease and more general declines in cognition,18,19 but hormone therapies may exacerbate cognitive decline when given only postmenopausally.18,19 Although trauma and PTSD often precede or coincide with depression and cognitive decline, the effects of perimenopause on trauma-related symptoms of PTSD and depression have received minimal research focus to date. A robust body of evidence suggests that women experience increased vulnerability for the development and exacerbation of mood symptoms during perimenopause. For instance, the risk for new-onset depression in women without a history of depression increases twofold during perimenopause,20 an effect that is exacerbated by exposure to early adverse experiences.21 Furthermore, multiple large cohort studies have shown that perimenopausal women report increased psychological distress, irritability, anxiety, nervousness, and depressive symptoms compared with premenopausal women.22–24 Because these changes in mood symptoms during perimenopause are linked to increased risk for all-cause mortality in women,25,26 it is important to determine factors that confer risk for trauma-related mood disruptions in women during midlife. Thus, in the current cross-sectional study, we assessed the relationship between stages of the menopause transition (premenopausal, perimenopausal, and postmenopausal) on symptoms of PTSD and depression in trauma-exposed women from an urban community sample recruited from waiting rooms at a public safety net hospital. We hypothesized that the perimenopausal and postmenopausal stages of the menopause transition, which are associated with alterations in hypothalamic-pituitary-ovarian function and hypogonadism, would be associated with greater symptoms of PTSD and depression compared with the premenopausal stage.

METHODS

Participants and study procedure

Study participants were approached randomly in the waiting rooms of nonpsychiatric medical clinics at Grady Memorial Hospital in Atlanta, Georgia, between 2005 and 2017.7,27 Participants were females between 18 and 65 years old who were not actively psychotic and able to give informed consent (n = 6,083). Enrolled participants completed a single study visit wherein sociodemographic information, lifetime trauma exposure, and PTSD and depressive symptoms were assessed. Initial interviews were conducted in the clinic waiting rooms by trained interviewers and included questionnaires regarding demographics, trauma history, and psychiatric symptoms. The Emory Institutional Review Board and the Grady Research Oversight Committee reviewed and approved all study procedures, and all participants gave informed consent before participation.

Measures

The Traumatic Events Inventory was used to measure lifetime trauma exposure and to a create a sum score of total number of different types of trauma exposure (eg, natural disasters, interpersonal violence/assault, motor vehicle crashes) each participant had been exposed to during their lifetime.28 Traumatic Events Inventory scores representing the total number of different traumas range from 0 to 13. The Childhood Trauma Questionnaire, a self-report measure of childhood abuse and neglect, was given to assess total childhood trauma severity.29 The Modified PTSD Symptom Scale was administered to capture total PTSD symptom severity as defined by the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition Text Revision).30,31 The Modified PTSD Symptom Scale is a validated 17-item self-report scale that captures PTSD symptoms in the last 2 weeks.31 Total PTSD symptom severity was calculated on a scale from 0 to 51, with higher scores representing more severe PTSD symptoms, as well as severity of each of the three symptoms clusters, including hyperarousal, avoidance/numbing, and intrusive symptoms. The Beck Depression Inventory II was used to capture depressive symptom severity. The Beck Depression Inventory II is a validated 21-item self-report measure of depressive symptom severity in the last 2 weeks, resulting in scores that range from 0 to 63.32 Sociodemographic data collected include self-reported sex, age, race, education, and monthly household income.28

Reproductive stage

Using self-reported age at time of study participation, we used age cutoffs to create a surrogate variable for reproductive stage, based on reported ages at the final menstrual period in two large longitudinal studies of the menopause transition: the Study of Women Entering and in Endocrine Transition (SWEET; mean age of 49.0 y at final menstrual period)33 and the Study of Women's Health Across the Nation (SWAN; median age of 52.5 y).34 Women younger than 40 years were categorized as premenopausal (n = 3,166); women between 40 and 55 years of age, as perimenopausal (n = 2,127); and women older than 55 years, as postmenopausal (n = 790).

Statistical analyses

Descriptive statistics were performed for sociodemographic information and trauma and childhood abuse exposure as a function of menopause status to identify covariates at an α level of P < 0.10. Analysis of covariance (ANCOVA) models adjusting for race, monthly household income, education, and lifetime trauma exposure and childhood abuse were used to assess the association between menopause stage and total PTSD and depression symptom severity, as well as PTSD subscale scores for hyperarousal, avoidance/numbing, and intrusive symptoms. A listwise deletion (complete-case analysis) approach was used to handle missing data for the linear regression. All data were analyzed using SPSS (v.28), and the α level was set at P ≤ 0.05.

RESULTS

Sociodemographic and trauma characteristics

The participants' demographic characteristics and trauma exposure and childhood abuse characteristics are summarized in Table 1 by menopause stage. The mean ± SEM ages for the premenopausal, perimenopausal, and postmenopausal groups were 27.0 ± 0.093, 48.2 ± 0.11, and 59.7 ± 0.19 years. Overall, 93.8% of participants were Black/African American, 2.5% were White, and 3.8% were of all other races (Hispanic/Latino, Asian, multiracial). Of all participants, 27.5% reported a monthly income of <$500, 25.1% reported a monthly income of <$1,000, and 46.6% a monthly income of >$1,000. In terms of educational attainment, 20.3% of participants had received less than a high school education, 39.6% completed high school or General Educational Development Test credential, and 40.1% received a greater than high school education. There was a main effect of menopause stage on lifetime trauma exposure (P < 0.001, η2 = 0.014) and childhood abuse (P < 0.001, η2 = 0.007). Perimenopausal women reported significantly greater trauma exposure than both premenopausal (P < 0.001) and postmenopausal women (P = 0.005). Premenopausal women reported greater trauma exposure than postmenopausal women (p's < 0.001; Table 1). Perimenopausal women reported significantly greater childhood abuse than both premenopausal and postmenopausal women (p's < 0.001; Table 1). Premenopausal women reported significant greater childhood abuse than postmenopausal women (P < 0.001; Table 1). Race (P = 0.025) and monthly income (P < 0.001) both varied by menopause stage, but education did not (P = 0.074; Table 1).

Table 1.

Sociodemographic information, trauma exposure characteristics, and symptom scores of participants by menopause stage

Pre
<40 y old n = 3,166
Peri
40-55 y old n = 2,127
Post >55 y old n = 790 Main effect of menopause stage P
Race X2 = 11.2 0.025
 Black 2,962 (93.6) 1,981 (93.1) 749 (94.8)
 White 66 (2.1) 69 (3.2) 16 (2.0)
 Othera 132 (4.2) 74 (3.5) 23 (2.9)
Monthly household income X2 = 53.2 <0.001
 <$500 846 (26.7) 625 (29.4) 143 (18.1)
 $500-$1,000 723 (22.8) 559 (26.3) 246 (31.1)
 >$1,000 1,470 (46.4) 895 (42.1) 379 (48.0)
Education X2 = 8.52 0.074
 < High school 646 (20.4) 418 (19.7) 167 (21.1)
 High school or GED 1,298 (41.0) 823 (38.7) 289 (36.6)
 > High school 1,218 (38.5) 883 (41.5) 333 (42.2)
TEI total types 3.52 ± 0.05 4.21 ± 0.06 3.89 ± 0.10 F2,5657 = 40.8 <0.001
CTQ 41.4 ± 0.33 43.3 ± 0.39 38.4 ± 0.65 F2,6021 = 20.9 <0.001
Total PTSD symptoms 12.4 ± 0.22 14.7 ± 0.26 11.1 ± 0.43 F2,6080 = 34.1 <0.001
PTSD hyperarousal symptoms 4.47 ± 0.08 5.33 ± 0.10 4.16 ± 0.16 F2,6072 = 32.0 <0.001
PTSD avoidance/numbing symptoms 4.90 ± 0.10 5.79 ± 0.12 4.33 ± 0.19 F2,6080 = 27.4 <0.001
PTSD intrusive symptoms 3.03 ± 0.07 3.57 ± 0.08 2.59 ± 0.13 F2,6080 = 23.8 <0.001
Depressive symptoms 14.1 ± 0.22 16.4 ± 0.27 12.5 ± 0.44 F2,5766 = 35.9 <0.001

Continuous variables are summarized as mean ± SEM, and categorical variables are presented as n (%).

CTQ, Childhood Trauma Questionnaire; GED, General Educational Development Test credential; PTSD, posttraumatic stress disorder; TEI, Traumatic Events Inventory.

a“Other” race category consisted of Hispanic/Latino, Asian, and multiracial individuals.

PTSD symptoms

ANCOVAs adjusting for race, income, education, and lifetime trauma exposure and childhood abuse showed a main effect of menopause stage on total PTSD symptom severity (F2,5416 = 9.61, P < 0.001, η2 = 0.004), hyperarousal symptoms (F2,5409 = 8.31, P < 0.001, η2 = 0.003), avoidance/numbing symptoms (F2,5416 = 7.10, P < 0.001, η2 = 0.003), and intrusive symptoms (F2,5416 = 7.04, P < 0.001, η2 = 0.003). Total PTSD symptom severity was greater in perimenopausal women compared with premenopausal and postmenopausal women (Table 2, Fig. 1A). Furthermore, postmenopausal women had significantly lower PTSD symptoms than premenopausal women (Table 2, Fig. 1A). Hyperarousal symptoms of PTSD were significantly greater in perimenopausal women compared with premenopausal and postmenopausal women (Table 2, Fig. 1B). Postmenopausal women had lower hyperarousal symptoms of PTSD than premenopausal women (Table 2, Fig. 1B). Avoidance/numbing symptoms of PTSD were greater in perimenopausal women compared with postmenopausal women (Table 2, Fig. 1C), but not premenopausal women (Table 2, Fig. 1C). Postmenopausal women had lower PTSD avoidance/numbing symptoms of PTSD than premenopausal women (Table 2, Fig. 1C). Finally, intrusive symptoms of PTSD were greater in perimenopausal women compared with postmenopausal (Table 2, Fig. 1D), but not premenopausal women (Table 2, Fig. 1D). Postmenopausal women had significantly lower intrusive symptoms than premenopausal women (Table 2, Fig. 1D).

Table 2.

Pairwise differences in estimated marginal means

Peri − Pre Peri − Post Pre − Post
Difference (95% CI) P Difference (95% CI) P Difference (95% CI) P
PTSD symptom severity 0.65 (0.5-1.24) 0.034 1.94 (1.07-2.82) <0.001 1.30 (0.46-2.13) 0.002
Hyperarousal symptoms 0.33 (0.10-0.55) 0.004 0.63 (0.31-0.95) <0.001 0.31 (−0.01 to 0.62) 0.055
Avoidance/numbing symptoms 0.21 (−0.06 to 0.48) 0.126 0.76 (0.37-1.16) <0.001 0.55 (0.17-0.93) 0.004
Intrusive symptoms 0.11 (−0.09 to 0.30) 0.281 0.54 (0.26-0.83) <0.001 0.44 (0.16-0.71) 0.002
Depressive symptoms 1.06 (0.44-1.69) <0.001 2.09 (1.18-3.01) <0.001 1.03 (0.15-1.90) 0.021

Differences are summarized as mean difference (95% CI), P value.

CI, confidence interval; PTSD, posttraumatic stress disorder.

FIG. 1.

FIG. 1

Effects of estimated menopause stage on PTSD symptoms. Mean ± SEM of (A) total PTSD symptom severity, (B) hyperarousal symptoms, (C) avoidance/numbing symptoms, and (D) intrusive symptoms of PTSD in premenopausal (Pre; <40 y), perimenopausal (Peri; 40-55 y), and postmenopausal (Post; >55 y) women. The mPSS was used to assess total PTSD symptom severity and symptom severity within each symptom cluster over the past 2 weeks. Asterisks denote significant differences between groups (** denotes P < 0.001 and * denotes P ≤ 0.05). mPSS, Modified PTSD Symptom Scale; PTSD, posttraumatic stress disorder.

Depressive symptoms

An ANCOVA adjusting for race, income, education, and lifetime trauma exposure and childhood abuse showed a main effect of menopause stage on total depression symptom severity (F2,5148 = 11.4, P < 0.001, η2 = 0.004). Symptoms of depression were greater in perimenopausal women compared with premenopausal women (P < 0.001; Fig. 2) and postmenopausal women (P < 0.001; Fig. 2). Postmenopausal women had significantly lower depression symptoms than both premenopausal and perimenopausal women (P = 0.021; Fig. 2).

FIG. 2.

FIG. 2

Effects of estimated menopause stage on depression symptoms. Mean ± SEM of total depression symptom severity in premenopausal (Pre; <40 y), perimenopausal (Peri; 40-55 y), and postmenopausal (Post; >55 y) women. Depression symptom severity over the past 2 weeks was assessed using the BDI II. Asterisks denote significant differences between groups (** denotes P < 0.001 and * denotes P ≤ 0.05). BDI II, Beck Depression Inventory II.

DISCUSSION

The current cross-sectional study found that menopausal status based on age was significantly associated with total PTSD symptom severity; PTSD symptom severity for the hyperarousal, avoidance/numbing, and intrusive symptom clusters; and depression symptom severity. Critically, within our large sample of trauma-exposed, predominantly African American women, perimenopausal women reported greater severity of total PTSD symptoms, greater severity within the hyperarousal PTSD symptom cluster, and elevated depression symptoms compared with both premenopausal and postmenopausal women. However, the results were not completely in line with our hypothesis, as postmenopausal women reported fewer PTSD and depression symptoms than both premenopausal and perimenopausal women. As Brinton and colleagues35 assert, perimenopause is a neurological, not merely a reproductive, transition state. The link between the menopause transition and mood symptoms has been gaining more attention in biomedical and psychiatric research, as perimenopause is characterized by not only changes in menstrual cycle patterns but also vasomotor symptoms (eg, hot flashes, sweating), fatigue, urinary and sexual discomfort, sleep patterns, and mood symptoms.36,37 For example, vasomotor symptoms and sleep disturbances appear to be driven by the effects of peripheral E2 variability and withdrawal,38 as the hypothalamus, critical for thermoregulation and the regulation of sleep, is sensitive to the variability in E2 levels because of a high concentration of estrogen receptors.37 To our knowledge, this is the first study to suggest that perimenopausal age may represent a period of elevated risk for PTSD symptomology.

Perimenopausal women report higher rates of psychological distress22 and are more likely to endorse persistent mood symptoms23 and more depression symptoms.39,40 Changes in hormone levels during perimenopause, specifically the variability in E2 and follicle-stimulating hormone levels, are associated with greater risk for the onset of depressive symptoms,24,41,42 even among women with no prior history of depression.43 Our findings of more severe depressive symptoms in the perimenopausal group compared with premenopausal and postmenopausal women in a trauma-exposed sample are in line with this overall pattern. Furthermore, trauma exposure has been previously linked to mood symptoms in older women: women with a history of physical abuse reported worse general well-being, worse psychological menopause symptoms, and greater depression symptoms during midlife.44 Again, it appears that the hallmark hormonal change during perimenopause—increased variability in E2 levels—is strongly related to the emergence of depressive symptoms and new diagnoses of depressive disorders.43

In addition, we found that women of perimenopausal age reported worse total PTSD symptoms and, specifically, greater symptom severity in the hyperarousal symptom cluster compared with both premenopausal and postmenopausal women. The highest prevalence rates of PTSD in women across the lifespan have been suggested to occur in the early 50s,45 coinciding with the menopausal transition. In naturally cycling women with PTSD, low E2 levels are associated with greater PTSD symptom burden and impaired fear extinction, a psychophysiological biomarker for PTSD.12 This finding is corroborated by functional magnetic resonance imaging data from premenopausal women indicating that E2 levels are positively associated with ventromedial prefrontal cortex (vmPFC) activation during fear extinction and with vmPFC and amygdala activation during extinction recall.46 PTSD is often conceptualized as a failure of fear extinction.47-50 Because the vmPFC and amygdala are critical areas involved in fear conditioning and extinction and contain a high concentration of estrogen receptors,46,51,52 variable fluctuations in E2 levels during perimenopause could exacerbate PTSD symptomology, specifically hyperarousal symptoms. Changes in other reproductive hormones, such as progesterone, luteinizing hormone, follicle-stimulating hormone, inhibin b, and antimüllerian hormone, may also contribute to the observed exacerbation of depressive and PTSD symptoms during perimenopause. For example, E2 and progesterone appear to have important functions for the molecular basis of learning and memory, through their involvement with synaptic plasticity and dendritic spine remodeling,46,53 and antimüllerian hormone augments synaptic strength and long-term potentiation in the hippocampus.54 More research across the translational science spectrum is necessary to better understand how changes in the multitude of hormones under the regulation of the hypothalamic-pituitary-ovarian axis during the menopause transition impact depressive and trauma-related symptoms.

It is notable that, for both PTSD and depression, symptoms were lowest in the postmenopausal window. It may be that trauma-related symptoms subside after E2 levels stop fluctuating, and brain circuits adapt to stable low levels of E2. However, known associations between traumatic stress and Alzheimer disease and related dementias55,56 suggest that there may be some effects of trauma that persist beyond the perimenopausal window. A major limitation of the present study was the use of age cutoffs to estimate menopausal status. Given the paucity of prior work on the relationship between reproductive aging and PTSD symptoms, we hope that these findings will support future studies in this field that use more specific criteria (eg, menstrual cycle patterns and hormone levels as per the STRAW+10 staging system15). Furthermore, the cross-sectional nature of the data precludes any conclusion of a causal relationship between perimenopausal age and elevated PTSD symptoms. In addition, although we were able to adjust for race, monthly household income, education, and lifetime trauma exposure and childhood abuse in the present analyses, there are many risk factors that may predispose individuals to psychiatric symptoms, including racial discrimination, living in socioeconomically disadvantaged areas, genetic risk factors and family histories of psychiatric illness, and limited social support. Future studies investigating the link between perimenopause and trauma-related psychiatric symptoms should aim to account for these factors. In addition, the current study sample was recruited from waiting rooms of nonpsychiatric waiting rooms at a large, safety net hospital in urban Atlanta. Varying factors may dissuade individuals from seeking medical care, such as discrimination, cultural norms and stigma, and financial concerns. Furthermore, our sample was predominantly Black/African American, with lifetime exposure to multiple different types of trauma. Therefore, these results may not generalize to other populations. The between-group differences in PTSD and depressive symptoms, although statistically significant, do not necessarily represent clinically meaningful differences. However, these findings suggest that additional investigation is needed. Longitudinal studies of trauma-exposed women from perimenopause through late aging will be necessary to disentangle these possibilities and understand the association between perimenopause and trauma-related psychiatric symptoms.

CONCLUSIONS

Taken together, the current data show that symptoms of PTSD and depression in trauma-exposed women may be impacted by reproductive stage, such that perimenopausal aged women report higher symptom severity than premenopausal and postmenopausal women. The association between perimenopausal age and PTSD symptom severity was driven by increased hyperarousal symptoms. Interestingly, postmenopausal women showed lower symptoms of PTSD compared with premenopausal women, suggesting that fluctuations rather than absolute levels of reproductive hormones may exacerbate risk for PTSD symptoms in trauma-exposed women. The current study is limited by its cross-sectional design, the use of self-report measures of PTSD and depressive symptoms, and the use of age as a surrogate marker of reproductive status as opposed to physiological and biological markers of the menopause transition (eg, STRAW+10 staging system15). Longitudinal studies are necessary to better understand how changes in reproductive hormones over the course of the menopause transition impact the symptoms, neurobiology, and psychophysiology of PTSD. These future studies will have critical implications for the prevention and intervention of trauma-related behavioral health outcomes in aging women.

Footnotes

Prior presentation of the abstract: “The Menopause Transition is Associated with Differences in PTSD and Depression Symptoms in Trauma-Exposed Black Women,” 60th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), San Juan, Puerto Rico, December 5-8, 2021.

Funding/support: This study was supported by MH115174 (V.M.), MH117009 (J.S.S.), AG062334 (V.M.), and MH128244 (V.M., J.S.S.). J.M.-K. has funding from Wounded Warrior Project, COMPASS Pathways, and Multidisciplinary Association of Psychedelic Studies and consulting payments from COMPASS Pathways.

Financial disclosure/conflicts of interest: None reported.

Contributor Information

Megan E. Huibregtse, Email: megan.elizabeth.huibregtse@emory.edu.

E. Britton Chahine, Email: e.britton.chahine@emory.edu.

Alicia K. Smith, Email: alicia.smith@emory.edu.

Ida T. Fonkoue, Email: fonko001@umn.edu.

Jessica Maples-Keller, Email: jmaple2@emory.edu.

Amy Murphy, Email: armurp3@emory.edu.

Linzie Taylor, Email: linzie.taylor@emory.edu.

Abigail Powers, Email: abigail.d.powers@emory.edu.

Jennifer S. Stevens, Email: jennifer.stevens@emory.edu.

REFERENCES

  • 1.Kilpatrick DG, Resnick HS, Milanak ME, Miller MW, Keyes KM, Friedman MJ. National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria. J Trauma Stress 2013;26:537–547. 10.1002/jts.21848 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.McKay MT Cannon M Chambers D, et al. Childhood trauma and adult mental disorder: a systematic review and meta-analysis of longitudinal cohort studies. Acta Psychiatr Scand 2021;143:189–205. 10.1111/acps.13268 [DOI] [PubMed] [Google Scholar]
  • 3.Hendrickson CM, Neylan TC, Na B, Regan M, Zhang Q, Cohen BE. Lifetime trauma exposure and prospective cardiovascular events and all-cause mortality: findings from the Heart and Soul Study. Psychosom Med 2013;75:849–855. 10.1097/PSY.0b013e3182a88846 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Medical comorbidity of full and partial posttraumatic stress disorder in US adults: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med 2011;73:697–707. 10.1097/PSY.0b013e3182303775 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 2006;27:2763–2774. 10.1093/eurheartj/ehl338 [DOI] [PubMed] [Google Scholar]
  • 6.Xia W Jiang H Di H, et al. Association between self-reported depression and risk of all-cause mortality and cause-specific mortality. J Affect Disord 2022;299:353–358. 10.1016/j.jad.2021.12.018 [DOI] [PubMed] [Google Scholar]
  • 7.Gluck RL Hartzell GE Dixon HD, et al. Trauma exposure and stress-related disorders in a large, urban, predominantly African-American, female sample. Arch Womens Ment Health 2021;24:893–901. 10.1007/s00737-021-01141-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Goldstein RB Smith SM Chou SP, et al. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Soc Psychiatry Psychiatr Epidemiol 2016;51:1137–1148. 10.1007/s00127-016-1208-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ursano RJ Fullerton CS Epstein RS, et al. Acute and chronic posttraumatic stress disorder in motor vehicle accident victims. Am J Psychiatry 1999;156:589–595. 10.1176/ajp.156.4.589 [DOI] [PubMed] [Google Scholar]
  • 10.Deecher D, Andree TH, Sloan D, Schechter LE. From menarche to menopause: exploring the underlying biology of depression in women experiencing hormonal changes. Psychoneuroendocrinology 2008;33:3–17. 10.1016/j.psyneuen.2007.10.006 [DOI] [PubMed] [Google Scholar]
  • 11.Altemus M. Neuroendocrine networks and functionality. Med Clin North Am 2019;103:601–612. 10.1016/j.mcna.2019.03.003 [DOI] [PubMed] [Google Scholar]
  • 12.Glover EM Jovanovic T Mercer KB, et al. Estrogen levels are associated with extinction deficits in women with posttraumatic stress disorder. Biol Psychiatry 2012;72:19–24. 10.1016/j.biopsych.2012.02.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Graham BM, Milad MR. Blockade of estrogen by hormonal contraceptives impairs fear extinction in female rats and women. Biol Psychiatry 2013;73:371–378. 10.1016/j.biopsych.2012.09.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Wegerer M, Kerschbaum H, Blechert J, Wilhelm FH. Low levels of estradiol are associated with elevated conditioned responding during fear extinction and with intrusive memories in daily life. Neurobiol Learn Mem 2014;116:145–154. 10.1016/j.nlm.2014.10.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Harlow SD Gass M Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause 2012;19:387–395. 10.1097/gme.0b013e31824d8f40 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Bromberger JT, Epperson CN. Depression during and after the perimenopause: impact of hormones, genetics, and environmental determinants of disease. Obstet Gynecol Clin North Am 2018;45:663–678. 10.1016/j.ogc.2018.07.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Schmidt PJ Ben Dor R Martinez PE, et al. Effects of estradiol withdrawal on mood in women with past perimenopausal depression: a randomized clinical trial. JAMA Psychiatry 2015;72:714–726. 10.1001/jamapsychiatry.2015.0111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Shao H Breitner JC Whitmer RA, et al. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology 2012;79:1846–1852. 10.1212/WNL.0b013e318271f823 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Whitmer RA, Quesenberry CP, Zhou J, Yaffe K. Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol 2011;69:163–169. 10.1002/ana.22239 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry 2006;63:385–390. 10.1001/archpsyc.63.4.385 [DOI] [PubMed] [Google Scholar]
  • 21.Epperson CN Sammel MD Bale TL, et al. Adverse childhood experiences and risk for first-episode major depression during the menopause transition. J Clin Psychiatry 2017;78:e298–e307. 10.4088/JCP.16m10662 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Bromberger JT Meyer PM Kravitz HM, et al. Psychologic distress and natural menopause: a multiethnic community study. Am J Public Health 2001;91:1435–1442. 10.2105/ajph.91.9.1435 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Bromberger JT, Assmann SF, Avis NE, Schocken M, Kravitz HM, Cordal A. Persistent mood symptoms in a multiethnic community cohort of pre- and perimenopausal women. Am J Epidemiol 2003;158:347–356. 10.1093/aje/kwg155 [DOI] [PubMed] [Google Scholar]
  • 24.Li RX, Ma M, Xiao XR, Xu Y, Chen XY, Li B. Perimenopausal syndrome and mood disorders in perimenopause: prevalence, severity, relationships, and risk factors. Medicine (Baltimore) 2016;95:e4466. 10.1097/MD.0000000000004466 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Smoller JW Pollack MH Wassertheil-Smoller S, et al. Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women's Health Initiative Observational Study. Arch Gen Psychiatry 2007;64:1153–1160. 10.1001/archpsyc.64.10.1153 [DOI] [PubMed] [Google Scholar]
  • 26.Wassertheil-Smoller S Shumaker S Ockene J, et al. Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI). Arch Intern Med 2004;164:289–298. 10.1001/archinte.164.3.289 [DOI] [PubMed] [Google Scholar]
  • 27.Gillespie CF Bradley B Mercer K, et al. Trauma exposure and stress-related disorders in inner city primary care patients. Gen Hosp Psychiatry 2009;31:505–514. 10.1016/j.genhosppsych.2009.05.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Binder EB Bradley RG Liu W, et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 2008;299:1291–1305. 10.1001/jama.299.11.1291 [pii] 10.1001/jama.299.11.1291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Bernstein DP, Ahluvalia T, Pogge D, Handelsman L. Validity of the Childhood Trauma Questionnaire in an adolescent psychiatric population. J Am Acad Child Adolesc Psychiatry 1997;36:340–348. 10.1097/00004583-199703000-00012 [pii] 10.1097/00004583-199703000-00012. [DOI] [PubMed] [Google Scholar]
  • 30.American Psychiatric Association, American Psychiatric Association. Task Force on DSM-IV . Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th ed,. Washington, DC: American Psychiatric Association; 2000. [Google Scholar]
  • 31.Falsetti SA, Resnick HS, Resick PA, Kilpatrick DG. The modified PTSD symptom scale: a brief self-report measure of posttraumatic stress disorder. Behav Ther 1993;16:161–162. [Google Scholar]
  • 32.Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571. 10.1001/archpsyc.1961.01710120031004 [DOI] [PubMed] [Google Scholar]
  • 33.Jaff NG, Snyman T, Norris SA, Crowther NJ. Staging reproductive aging using Stages of Reproductive Aging Workshop +10 in black urban African women in the Study of Women Entering and in Endocrine Transition. Menopause 2014;21:1225–1233. 10.1097/GME.0000000000000235 [DOI] [PubMed] [Google Scholar]
  • 34.Gold EB Crawford SL Avis NE, et al. Factors related to age at natural menopause: longitudinal analyses from SWAN. Am J Epidemiol 2013;178:70–83. 10.1093/aje/kws421 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Brinton RD, Yao J, Yin F, Mack WJ, Cadenas E. Perimenopause as a neurological transition state. Nat Rev Endocrinol 2015;11:393–405. 10.1038/nrendo.2015.82 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Bruce D, Rymer J. Symptoms of the menopause. Best Pract Res Clin Obstet Gynaecol 2009;23:25–32. 10.1016/j.bpobgyn.2008.10.002 [DOI] [PubMed] [Google Scholar]
  • 37.Rossmanith WG, Ruebberdt W. What causes hot flushes? The neuroendocrine origin of vasomotor symptoms in the menopause. Gynecol Endocrinol 2009;25:303–314. 10.1080/09513590802632514 [DOI] [PubMed] [Google Scholar]
  • 38.Gallicchio L, Whiteman MK, Tomic D, Miller KP, Langenberg P, Flaws JA. Type of menopause, patterns of hormone therapy use, and hot flashes. Fertil Steril 2006;85:1432–1440. 10.1016/j.fertnstert.2005.10.033 [DOI] [PubMed] [Google Scholar]
  • 39.Bromberger JT Matthews KA Schott LL, et al. Depressive symptoms during the menopausal transition: the Study of Women's Health Across the Nation (SWAN). J Affect Disord 2007;103(1-3):267–272. 10.1016/j.jad.2007.01.034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61:62–70. 10.1001/archpsyc.61.1.62 [DOI] [PubMed] [Google Scholar]
  • 41.Schmidt PJ, Haq N, Rubinow DR. A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am J Psychiatry 2004;161:2238–2244. 10.1176/appi.ajp.161.12.2238 [DOI] [PubMed] [Google Scholar]
  • 42.Steinberg EM Rubinow DR Bartko JJ, et al. A cross-sectional evaluation of perimenopausal depression. J Clin Psychiatry 2008;69:973–980. 10.4088/jcp.v69n0614 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006;63:375–382. 10.1001/archpsyc.63.4.375 [DOI] [PubMed] [Google Scholar]
  • 44.Faleschini S Tiemeier H Rifas-Shiman SL, et al. Longitudinal associations of psychosocial stressors with menopausal symptoms and well-being among women in midlife. Menopause 2022;29:1247–1253. 10.1097/GME.0000000000002056 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Ditlevsen DN, Elklit A. The combined effect of gender and age on post traumatic stress disorder: do men and women show differences in the lifespan distribution of the disorder? Ann Gen Psychiatry 2010;9:32. 10.1186/1744-859X-9-32 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Zeidan MA Igoe SA Linnman C, et al. Estradiol modulates medial prefrontal cortex and amygdala activity during fear extinction in women and female rats. Biol Psychiatry 2011;70:920–927. 10.1016/j.biopsych.2011.05.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Norrholm SD Glover EM Stevens JS, et al. Fear load: The psychophysiological over-expression of fear as an intermediate phenotype associated with trauma reactions. Int J Psychophysiol 2015;98(2 Pt 2):270–275. 10.1016/j.ijpsycho.2014.11.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Norrholm SD Jovanovic T Olin IW, et al. Fear extinction in traumatized civilians with posttraumatic stress disorder: relation to symptom severity. Biol Psychiatry 2011;69:556–563. 10.1016/j.biopsych.2010.09.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Jovanovic T, Norrholm SD. Neural mechanisms of impaired fear inhibition in posttraumatic stress disorder. Front Behav Neurosci 2011;5:44. 10.3389/fnbeh.2011.00044 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Rothbaum BO, Davis M. Applying learning principles to the treatment of post-trauma reactions. Ann N Y Acad Sci 2003;1008:112–121. 10.1196/annals.1301.012 [DOI] [PubMed] [Google Scholar]
  • 51.Ostlund H, Keller E, Hurd YL. Estrogen receptor gene expression in relation to neuropsychiatric disorders. Ann N Y Acad Sci 2003;1007:54–63. 10.1196/annals.1286.006 [DOI] [PubMed] [Google Scholar]
  • 52.Galvin C, Ninan I. Regulation of the mouse medial prefrontal cortical synapses by endogenous estradiol. Neuropsychopharmacology 2014;39:2086–2094. 10.1038/npp.2014.56 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Woolley CS, McEwen BS. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J Comp Neurol 1993;336:293–306. 10.1002/cne.903360210 [DOI] [PubMed] [Google Scholar]
  • 54.Wang K Xu F Campbell SP, et al. Rapid actions of anti-Mullerian hormone in regulating synaptic transmission and long-term synaptic plasticity in the hippocampus. FASEB J 2020;34:706–719. 10.1096/fj.201902217R [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Desmarais P Weidman D Wassef A, et al. The interplay between post-traumatic stress disorder and dementia: a systematic review. Am J Geriatr Psychiatry 2020;28:48–60. 10.1016/j.jagp.2019.08.006 [DOI] [PubMed] [Google Scholar]
  • 56.Burnes DP, Burnette D. Broadening the etiological discourse on Alzheimer's disease to include trauma and posttraumatic stress disorder as psychosocial risk factors. J Aging Stud 2013;27:218–224. 10.1016/j.jaging.2013.03.002 [DOI] [PubMed] [Google Scholar]

Articles from Menopause (New York, N.y.) are provided here courtesy of Wolters Kluwer Health

RESOURCES